#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

Apr 20, 2026 Episode Page ↗
Overview

Peter Attia, MD, discusses how outdated prostate cancer screening guidelines have led to a rise in advanced disease. He advocates for modern screening using longitudinal PSA trends, MRI, and improved biopsies, highlighting finasteride's impact on PSA and the potential to eradicate prostate cancer mortality.

At a Glance
11 Insights
46m 21s Duration

Deep Dive Analysis

1. Adjust PSA for Finasteride

If taking finasteride for a year or longer, double your PSA value for correct interpretation; apply a 2.3x multiplier after 2-7 years and 2.5x beyond 7 years to account for drug-induced suppression. This adjustment is crucial because finasteride significantly reduces PSA production, masking potential cancer.

2. Track PSA as a Trend

Interpret PSA values as a longitudinal trend (PSA velocity) rather than a single snapshot, as individual readings are noisy and fluctuate. Tracking changes over time provides a more accurate signal of prostate health.

3. Treat Any PSA Rise on Finasteride as Serious

If on long-term finasteride, any upward movement in PSA should be considered a serious warning sign, as the drug’s suppression should offset natural age-related increases. This indicates a potential underlying issue that requires immediate attention.

4. Inform Doctors About All Medications

Ensure your doctor is aware of all prescriptions, especially 5-alpha reductase inhibitors like finasteride, to enable correct interpretation of PSA results. Many physicians are unaware of finasteride’s PSA-suppressing effects, leading to missed diagnoses.

5. Utilize Specific PSA Velocity Thresholds

Flag a sustained PSA rise of more than 0.35 ng/mL per year over 18 months for baselines under 4 ng/mL, or 0.75 ng/mL per year for baselines above 4 ng/mL. Rapid increases are a key indicator of potential pathological changes.

6. Follow Up PSA Velocity with MRI

If PSA velocity flags a concern, the next step should be an MRI, which is a higher-resolution and less invasive test than immediately proceeding to a biopsy. MRI can identify suspicious lesions and guide further action.

7. Incorporate PSA Density for Risk Assessment

Use PSA density (PSA concentration divided by prostate volume from imaging) as an additional metric. A disproportionate rise in PSA relative to prostate volume indicates that something is wrong, as malignancy can cause PSA to leak into the bloodstream at an accelerated rate.

8. Opt for Contrast-Free Bi-parametric MRI

When an MRI is needed, consider a contrast-free bi-parametric MRI, as studies show it performs as well as the full multi-parametric MRI for detecting clinically significant cancer. This reduces cost, time, and the need for gadolinium contrast.

9. Request Transperineal Prostate Biopsy

If a biopsy is warranted, request a transperineal approach, which bypasses the rectum to dramatically reduce infection risk and provides better access to the prostate. This method also detects more high-grade cancers and fewer low-grade ones.

10. Consider Active Surveillance for Low-Grade Cancers

For low-risk prostate cancers (Gleason Grade Group 1 or 2), discuss active surveillance with your urologist instead of immediate treatment. This approach monitors the cancer to avoid overtreatment and its associated side effects for indolent tumors.

11. Prioritize Early Prostate Cancer Detection

Actively pursue regular PSA testing and modern screening methods, as early detection of prostate cancer significantly improves prognosis, with a 15-year survival rate approaching 97% for early diagnoses. Prostate cancer is highly curable when caught before metastasis.